BOCA RATON, Fla.–(BUSINESS WIRE)–SurGenTec® has been issued device and method patent No. 9,668,881 from the United States Patent and Trademark Office for its graft loading technology to post-fill implant cages. The Graftgun® is a universal graft delivery system that allows surgeons to use the bone graft of their choice. The device permits minimally invasive delivery of bone graft material into bone voids, disc spaces, cages, and implants. Once the implant has been positioned and the inserter is removed, the device can be connected to post-fill a variety of implants. The Graftgun kit will include a universal loading device which enables surgeons to load allograft, autograft, or synthetic biologics into the gun’s delivery tube and dispense it to an orthopedic site.

“We now have intellectual property that protects our ability to post-fill cages in situ,” said Travis Greenhalgh, CEO of SurGenTec. “One of the challenges when using expandable or monolithic cages is the ability to post-fill them once inserted into the disc space. The traditional way to post-fill a cage is to use a funnel or an elongated syringe. Most types of bone graft require significant force to extrude the material into the aperture of a cage. Our ratcheting technology provides users the force needed to extrude an array of bone graft materials, while maintaining superior control of the amount of graft that enters the cage and disc space. A concern with expandable cages is the ability to pack the implant with enough bone graft to provide maximum endplate contact. If there is a void between the bone graft and endplate there may be a higher risk of non-unions. The Graftgun ratcheting technology can help ensure the void is filled.”

SurGenTec has the capacity to customize the Graftgun so that it can be paired with nearly any cage on the market without requiring changes to their instruments. This will allow implant manufacturers seamless access to the Graftgun’s innovative technology, and the ability to offer an advantageous graft delivery solution to their end users. With the expandable cage market growing, this should be a viable option to optimize graft volume within a variety of implants.

SurGenTec looks forward to becoming the leader in bone graft delivery technologies, and has allocated a considerable amount of resources to ensure that they are on the forefront of this sector of orthopedic and spine surgery.

SurGenTec is a privately owned medical device company based out of Boca Raton, FL. They are focused on developing minimally invasive surgical technologies to help surgeons provide optimal care for their patients. SurGenTec anticipates the Graftgun to be released this summer.

BURLINGTON, Mass.–(BUSINESS WIRE)–Bone Biologics Corp. (OTCQB: BBLG) announced that Bret Hankey has joined the company’s board of directors. Mr. Hankey brings more than 15 years of operating and board director experience to the BBLG board.

Since 2000, Mr. Hankey, age 40, has served in various capacities within the Hankey Group where he currently serves as President and is a member of the board of directors on all major companies that comprise the Hankey Group.

Headquartered in Los Angeles, California, the Hankey Group is comprised of seven operating companies specializing primarily in the automotive, finance, technology, real estate and insurance industries. Since 2007, Mr. Hankey has also served in various capacities with Westlake Financial Services, a member of the Hankey Group, and is currently the Vice Chairman and Executive Vice President of Westlake Financial. Westlake Financial is the largest privately held automotive finance company in the United States. Mr. Hankey graduated from the University of Southern California in 2000 with a B.S. in Business Administration and Finance.

About Bone Biologics

Bone Biologics (OTCQB:BBLG) was founded to pursue regenerative medicine for bone.

Bone Biologics Corporation is undertaking groundbreaking work with the three founders and select strategic partners, building on unprecedented research on the Nell-1 molecule that has produced a significant number of studies and publications in peer reviewed scientific literature.

Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion. Nell-1 is a recombinant human protein growth factor that is essential for normal bone development.

For more information, please visit the company’s website at www.bonebiologics.com.

Bone Biologics trades on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies. OTCQB companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.

About The Hankey Group

Headquartered in Los Angeles, California, the Hankey Group is comprised of seven operating companies specializing primarily in the automotive, finance, technology, real estate and insurance industries.

Forward-Looking Statements

This press release contains forward-looking statements that reflect the Company’s current beliefs, expectations or intentions regarding future events. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “will,” “will be,” “anticipate,” “predict,” “continue,” “future,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to trading in the Company’s common stock on the OTCQB; the next phase of the Company’s development and testing work; the Company’s expectation about moving its technology forward and setting the stage for future growth and enhanced shareholder value; and the future need for regenerative bone solutions. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: future revenues, expenditures, capital or other funding requirements, the adequacy of the Company’s current cash and working capital to fund present and planned operations and financing needs, expansion of and demand for product offerings, and the growth of the Company’s business and operations through acquisitions or otherwise, as well as future economic and other conditions both generally and in the Company’s specific geographic and product markets. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent current report on Form 10-K, filed with the Securities and Exchange Commission on March 30, 2017 and Form 10-Q, filed with the Securities and Exchange Commission on May 12, 2017. The Company anticipates that subsequent events and developments may cause their views and expectations to change. The Company assumes no obligation, and they specifically disclaim any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Disclaimer

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

LEXINGTON, Ky.–(BUSINESS WIRE)–Based on 12-month follow-up clinical data from its safety and feasibility study, Intralink-Spine, Inc. (ILS) indicates that the Réjuve™ System continues to effectively eliminate or reduce low back pain and disability associated with degenerative disc disease.

“We continue to be very pleased with the patient outcomes,” states Dr. Tom Hedman, Ph.D., the inventor and Adjunct Associate Professor in the F. Joseph Halcomb III, M.D. Department of Biomedical Engineering at the University of Kentucky. “Twelve months after the Réjuve procedure, three of the four (3/4) patients eligible for this follow-up assessment have no (zero) low back pain and no (zero) disability. And, the fourth patient has minimal pain and disability. These initial clinical results demonstrate a long-lasting, significant reduction or elimination of pain and disability, not just a slight reduction, and these benefits began within days of the initial procedure. We also have objective imaging data demonstrating the elimination of clinical instability. This is great news, especially as we begin our larger pivotal clinical studies.” (Video – Dr. Hedman discusses recent clinical data.)

“With the reduction or elimination of low back pain coming so quickly after the procedure, skeptics were reluctant to believe that the Réjuve treatment would actually stay the course. And, I understand their skepticism, because alternative treatments with good early results have turned out to only be temporary and with biologic treatments, good results require months or years to take effect, if they come at all,” says Lyle Hawkins, CEO of Intralink-Spine, Inc. “Now, they see data from us that patients improve within days of treatment and continue to enjoy a better quality of life 12 months post procedure. So, yes, they were skeptical. However, we’re beginning to turn skeptics into believers.”

According to Hawkins, “We understand that we need to evaluate this injectable device in a much larger group of patients in a multisite study, but we are very optimistic as we pursue that next milestone. We believe the Réjuve System which structurally reinforces the native intervertebral disc itself is going to be a better treatment option for many patients with low back pain. Réjuve has the procedural simplicity of an epidural steroid injection, but with potential long-term positive effects similar to a successful fusion.”

About Intralink-Spine, Inc. (ILS): Formed to manufacture and exclusively sell the Réjuve™ injectable medical device to treat Degenerative Disc Disease (DDD), low back pain, and related spinal diseases such as scoliosis, ILS is currently conducting a Round C fundraising event for accredited investors.

SAN DIEGO–(BUSINESS WIRE)–Samumed, a leader in cartilage regeneration research, today announced the successful completion of a 52-week Phase II clinical trial of its potential treatment for osteoarthritis (“OA”) of the knee. SM04690 is a novel, small molecule inhibitor of the Wnt pathway, administered as an intra-articular injection. SM04690 appeared safe and well-tolerated at all dose levels studied. There were 29 serious adverse events reported, none of which were deemed related to SM04690, as assessed by the investigators. A detailed analysis of 52-week results of this Phase II study, including safety, pain and function scores, and disease modification, will be presented at future medical conferences.

“The completion of our Phase II clinical trial of SM04690 for the potential treatment of OA of the knee marks an important milestone for physicians, patients, and our development program,” said Dr. Yusuf Yazici, Samumed’s Chief Medical Officer. “While the current standard of care is focused on relieving signs and symptoms of the disease, SM04690 has the potential to be the first disease-modifying treatment approved for OA of the knee.”

Samumed presented 26-week interim data last month at the annual European League Against Rheumatism (EULAR) Congress in Madrid, Spain. SM04690, studied as a once annual injection, showed promising efficacy and safety at the six-month timepoint. The product appeared to potentially regrow cartilage, as demonstrated by increased medial joint space width on x-ray of the treated knee, and also appeared to improve both pain and function scores in patients compared to placebo. The presentations can be viewed at: http://bit.ly/2tZVN2lhttp://bit.ly/2sBTimi

SM04690 is in development as a potential disease modifying drug for knee OA (DMOAD) designed to increase chondrocyte production to generate new articular cartilage, reduce protease production to slow down cartilage degradation, and reduce inflammation in the joint. This Phase II trial was a randomized, double-blind, placebo-controlled study, to determine the safety and efficacy of SM04690. The study enrolled across 36 clinical sites in the US a total of 455 patients with moderate-to-severe OA of the knee. Subjects received a single injection of SM04690, with pain and function scores assessed by WOMAC and disease modification assessed by medial joint space width by x-ray. Study details can be reviewed at: http://bit.ly/2eOINuv

About Osteoarthritis (OA)

Arthritis is the most common cause of disability among adults, and OA is the most common type of arthritis, accounting for much of this burden. The overall number of US adults affected by OA in any joint has increased during recent decades, to 27 million in 2005, primarily due to an aging population and an ever-increasing prevalence of obesity. OA is characterized by pain, disability and joint deformity due to articular cartilage degradation and bone remodeling.

About Samumed, LLC

Based in San Diego, CA, Samumed (www.samumed.com) is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation. Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer.

SAN ANTONIO–(BUSINESS WIRE)–Tissue Regenix, the UK-based regenerative medical devices company, today announced the proposed acquisition of CellRight Technologies, a U.S. regenerative medicine company based in San Antonio, TX. This acquisition would bring together two highly complementary technology and product platforms focused on soft-tissue regeneration and regenerative bone matrices, respectively.

The deal accelerates both companies’ vision to becoming a global leader in regenerative medicine by accelerating growth and penetration into key U.S. markets. The combined group will have a highly complementary product offering with CellRight Technologies’ existing orthopedic portfolio, based on human-derived bone graft products, and Tissue Regenix’s soft tissue products based on its patented decellularisation dCELL® Technology (dCELL®), a multi-tissue regenerative medical platform.

The combined group provides CellRight Technologies with the infrastructure of a larger, multi-national organization and a platform to enter new geographies. CellRight Technologies’ human tissue-based products, including Matrix OI, will expand the current Tissue Regenix portfolio, which includes DermaPure® for wound care applications. Additionally, CellRight Technologies’ existing tissue bank in San Antonio, TX, provides Tissue Regenix with a purpose built U.S. base to self-manufacture products utilizing its patented dCELL® process.

Combined with the capabilities of CellRight Technologies’ osteobiologics, this acquisition positions Tissue Regenix to launch into the U.S. orthopedics market in early 2018 with a focus on ligament reconstruction, initially addressing anterior cruciate ligament repair, through OrthoPure® HT, a decellularised human tendon.

“We are excited by the huge potential that this acquisition brings for the advancement of regenerative medicine to our patients globally,” said Antony Odell, CEO of Tissue Regenix. “We are combining two highly complementary companies that are committed to developing a robust portfolio of products and we are poised for rapid growth through our existing product offering with plans for multiple U.S. launches over the next two years.”

CellRight Technologies has seen tremendous success in the U.S., including leveraging strong relationships with orthopedics and sports medicine companies. Founder and CEO Jesus Hernandez has been at the heart of research and development for the CellRight Technologies product line.

“Becoming part of the Tissue Regenix family is an exciting and important milestone for our company,” said Jesus Hernandez, founder and CEO of CellRight Technologies. “With the combined talent and expertise in biologics, we look forward to continuing to lead regenerative medicine, bringing our patients and healthcare partners the products and innovation which enhance their lives. We are all excited at the potential of what we will be able to accomplish together.”

For more information about Tissue Regenix, please visit http://www.tissueregenix.com/.

Important notice

The information contained herein is not for release, directly or indirectly, in or into Australia, Canada, Japan or the Republic of South Africa. This document (and the information contained herein) does not contain or constitute an offer of securities for sale, or solicitation of an offer to purchase securities, in the United States, Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction where such an offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States unless the securities are registered under the Securities Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No public offering of the securities will be made in the United States.

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®’) Technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

About CellRight Technologies

CellRight Technologies is the industry leader of osteoinductive matrices and is committed to providing clinicians and their patients with verified osteoinductive implants known to positively impact patient and fusion outcomes. In-vivo and in-vitro testing to verify osteoinductivity is performed post-sterilization by an independent testing laboratory using validated osteoinductivity test methods.